目的 探讨复方苦参肠炎康片联合柳氮磺吡啶治疗溃疡性结肠炎的临床效果。方法 选取2019年3月—2021年7月亳州市人民医院收治的118例溃疡性结肠炎患者，随机分成对照组和治疗组，每组各59例。对照组口服柳氮磺吡啶肠溶片，4片/次，3次/d。在对照组基础上，治疗组口服复方苦参肠炎康片，4片/次，3次/d。两组患者连续治疗8周。观察两组患者临床疗效，比较治疗前后两组患者典型表现评分，改良Mayo评分和炎症性肠病问卷（IBDQ）总分，及血清肿瘤坏死因子-α（TNF-α）、白细胞介素-17（IL-17）和单核细胞趋化蛋白-1（MCP-1）水平。结果 治疗后，治疗组临床有效率（94.92%）较对照组（83.05%）显著增高（P＜0.05）。治疗后，两组腹痛、脓血便及腹泻评分均显著低于治疗前（P＜0.05），且以治疗组的下降更显著（P＜0.05）。与治疗前对比，两组治疗后改良Mayo评分均显著减少，而IBDQ总分则均显著增加（P＜0.05），且以治疗组2项评分改善更显著（P＜0.05）。治疗后，两组血清TNF-α、IL-17和MCP-1水平均显著低于治疗前（P＜0.05），且治疗后治疗组患者血清TNF-α、IL-17和MCP-1水平的降低水平较对照组更显著（P＜0.05）。结论 复方苦参肠炎康片联合柳氮磺吡啶对溃疡性结肠炎患者具有确切的临床疗效，可有效减轻患者症状、促进病情缓解及改善生活质量，并能进一步抑制患者体内炎症反应，且安全性较好。

Objective To explore the clinical effect of Compound Kushen Changyankang Tablets combined with sulfasalazine in treatment of ulcerative colitis. Methods Patients (118 cases) with ulcerative colitis in Bozhou People's Hospital from March 2019 to July 2021 were randomly divided into control and treatment group, and each group had 59 cases. Patients in the control group were po administered with Sulfasalazine Enteric-coated Tablets, 4 tablets/time, three times daily. Patients in the treatment group were po administered with Compound Kushen Changyankang Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical evaluation was evaluated, the typical performance scores, modified Mayo scores and IBDQ total scores, and the serum levels of TNF-α, IL-17 and MCP-1 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group[94.92% (56/59)] was significantly higher than that of the control group[83.05% (49/59)] (P < 0.05). After treatment, the scores of abdominal pain, purulent and bloody stool and diarrhea in two groups were significantly lower than those before treatment (P < 0.05), especially in the treatment group (P < 0.05). Compared with those before treatment, the modified Mayo score were significantly decreased, while the total score of IBDQ were significantly increased in two groups after treatment (P < 0.05), especially in the treatment group (P < 0.05). After treatment, the levels of serum TNF-α, IL-17 and MCP-1 in two groups were significantly lower than those before treatment (P < 0.05), and the levels of serum TNF-α, IL-17 and MCP-1 in the treatment group were more significantly lower than those in the control group (P < 0.05). Conclusion Compound Kushen Changyankang Tablets combined with sulfasalazine in treatment of ulcerative colitis has definite clinical effect, can effectively reduce the symptoms of patients, promote the remission of the disease and improve the quality of life, and can further inhibit the inflammatory reaction in patients, and it is safe.

R975

亳州市重点研发计划项目(bzzc2021023)